

May 19, 2026

To,  
**BSE Limited**  
Phirozee Jeejeebhoy Towers,  
Dalal Sreet, Fort,  
Mumbai-400001

Dear Sir/Madam,

**Sub.: Open Offer by Harmony Remedies India Private Limited (“Acquirer”), along with Mr. Firoze Nariman Kapadia (PAC 1) and Ms. Aditi Vipin Parikh (PAC 2) Representing Directors of Acquirer , hereinafter collectively referred as Person acting in concerts or PACs for the purpose of the Open Offer, to the public shareholders of N2N Technologies Limited (“Target Company”) for acquisition of up to 12,91,228 equity shares of face value of ₹ 10/- each at a price of ₹ 4.30/- per fully paid up equity share representing 40% of the Expanded Voting Capital, pursuant to regulations 4 and other applicable provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (“SEBI (SAST) Regulations”).**

This has reference to the captioned Open Offer, and our letters dated October 27, 2025, November 03, 2025, November 11, 2025, April 20, 2026, April 23, 2026 and April 29, 2026 for submission of Public Announcement, Detailed Public Statement, Draft Letter of Offer (DLOF), Letter of Offer (LOF), IDC Recommendation and Offer Opening Public Announcement and Corrigendum to Detailed Public Statement respectively.


In terms of Regulation 18(12) of the Takeover Regulations Post Offer Advertisement has been published on May 19, 2026, in the same newspapers where Detailed Public Statement (“DPS”) of the Open Offer was published i.e.

Newspapers	Language	Edition
Financial Express	English national daily	All editions
Jansatta	Hindi national daily	All editions
Tarun Bharat	Marathi	Pune
Navshakti	Marathi	Mumbai

As the equity shares of Target Company are listed on your Stock Exchange, in terms of Regulation 18(12)(b)(ii), please find enclosed soft copy of Post Offer Advertisement for your records. Kindly disseminate the same.

Yours faithfully

For Inga Ventures Private Limited

  
Name: Kavita Shah  
Designation: Partner



Encl: As above.

**PURAVANKARA****PURAVANKARA LIMITED**

(CIN: L45200KA1986PLC051571)

Registered Office: No. 130/1, Ulsoor Road, Bangalore – 560 042

Tel: 080 2559 9000/4343999

Email: investors@puravankara.com Website: www.puravankara.com

**STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026**

The Audited Standalone and Consolidated Financial Results of Puravankara Limited ("the Company") along with the Statutory Auditors Report for the quarter and financial year ended March 31, 2026, reviewed by the Audit Committee and approved by Board of Directors of the Company at its Meeting held on Monday, May 18, 2026, in terms of Regulation 33 read with Regulation 47(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforementioned Financial Results along with the Statutory Auditors Report thereon are available on the website of BSE Limited (BSE) (www.bseindia.com) and National Stock Exchange of India Limited (NSE) (www.nseindia.com) and on the Company's website at www.puravankara.com. The same can be accessed by scanning the Quick Response Code provided below:

Date: May 18, 2026  
Place: BangaloreBy order of Board of Directors  
For Puravankara Limited  
Sd/-Ashish Ravi Puravankara  
Managing Director  
DIN: 00504524

(Please scan the QR to view the Draft Red Herring Prospectus)

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSE ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES IN COMPLIANCE WITH CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")

**PUBLIC ANNOUNCEMENT****HIMALAYA NUTRAVEDICS INDIA LIMITED**

(Formerly Known as Himalaya Nutravedics India Private Limited)

CIN: U24110TG2022PLC163732

Our Company was originally incorporated and registered as a private limited company under the Companies Act, 2013 under the name of 'Himalaya Nutravedics India Private Limited' on June 16, 2022 bearing Corporate Identification Number U24110TG2022PTC163732 Issued by the Registrar of Companies, Central Registration Centre. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our members at the Extra Ordinary General Meeting held on November 28, 2025 and consequently the name of our Company was changed to 'Himalaya Nutravedics India Limited'. A fresh certificate of incorporation consequent upon conversion from private limited company to public limited company dated December 12, 2025, was issued by Registrar of Companies, Central Processing Centre bearing Corporate Identification Number U24110TG2022PLC163732.

For details of incorporation and change in the name of our Company, please refer to the chapter titled "History and Corporate Structure" beginning on page 202 of the Draft Red Herring Prospectus.

Registered and Corporate Office: Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally,

Hindustan Cables Ltd, Uppal, Hyderabad - 500051, Telangana, India

Telephone: +91 9063498493; Website: www.himalayanutravedics.com; E-mail: info@himalayanutravedics.com

Contact Person: Pooja Biyani (Company Secretary and Compliance Officer); CIN: U24110TG2022PLC163732

**PROMOTERS OF OUR COMPANY - ROHIT ASAWA, DIVYA ASAWA, CHANDA ASAWA AND RAMA RAJU PENMATSA**

INITIAL PUBLIC ISSUE OF UPTO 25,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF THE COMPANY AT AN ISSUE PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [•] LAKHS ("PUBLIC ISSUE"), OUT OF WHICH [•] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH, AT AN ISSUE PRICE OF ₹[•] PER EQUITY SHARE FOR CASH, AGGREGATING ₹[•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [•] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹[•] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[•] LAKHS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [•]% AND [•]% RESPECTIVELY OF THE POSTISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN ALL EDITIONS OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF THE TELUGU DAILY NEWSPAPER, [•] (TELUGU BEING THE REGIONAL LANGUAGE OF TELANGANA, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED (BSE SME) FOR THE PURPOSES OF UPLOADING ON ITS WEBSITE IN ACCORDANCE WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three (3) additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten (10) Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten (10) Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229(1) of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved for domestic mutual funds and life insurance companies and pension funds, out of which 33.33% shall be reserved for domestic Mutual Funds, subject to valid bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors out of which (a) one third of such portion was reserved for applicants with Bid cum application size of more than 2 lots and up to such lots equivalent to not more than ₹ 10.00 Lakhs and (b) two-third of such portion was reserved for applicants with Bid cum application size of more than ₹ 10.00 Lakhs provided that the unsubscribed portion in either of such subcategories could have been allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations. All Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 284 of the Draft Red Herring Prospectus.

This Public Announcement is made in compliance with the provisions of Regulation 247 of SEBI ICDR Regulations and SEBI (ICDR) Amendment Regulations, 2025 vide notification dated March 03, 2025 and applicability under of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Issue and DRHP dated May 15, 2026 which has been filed with the SME Platform of BSE Limited.

Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03<sup>rd</sup> 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME Companies, for fulfilling all additional eligibility criteria, the DRHP [along with Draft Abridge Prospectus] filed with Stock Exchange i.e. SME Platform of BSE shall be made public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE i.e. <https://www.bsesme.com> where equity shares are proposed to be listed, on the website of the Company i.e. <https://www.himalayanutravedics.com>; and the website of the Book Running Lead Manager ("BRLM"), i.e. Nirbhaya Capital Services Private Limited at [www.nirbhayacapital.com](http://www.nirbhayacapital.com). Our Company hereby invites members of the public to give their comments on the DRHP [along with Draft Abridge Prospectus] filed with Stock Exchange shall be SME platform of BSE, with respect to disclosures made in the DRHP [along with Draft Abridge Prospectus]. The members of the public are requested to send a copy of their comments to Stock Exchange i.e. SME platform of BSE and to the Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by Stock Exchange and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs on or before 5.00 p.m. on the 21<sup>st</sup> day from the aforesaid date of filing the DRHP with SME Platform of BSE Limited.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 26 of the Draft Red Herring Prospectus.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the SME Platform of BSE.

For details of the share capital and capital structure of our Company and the name of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company please see the section titled 'Capital Structure' beginning on page 80 of the DRHP. The liability of members of our Company is limited.

For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled 'History and Corporate Structure' on page 202 of the DRHP.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>NIRBHAY CAPITAL SERVICES PRIVATE LIMITED</b> Address: 201, Maruti Crystal, Opposite Rajpath Club, S.G. Highway, Ahmedabad-380054, Gujarat, India Tel No.: +91 7948970649 Email: kunjaj@nirbhaycapital.com Investor Grievance ID: ipo@nirbhaycapital.com Website: www.nirbhaycapital.com Contact Person: Kunjal Soni SEBI Registration No: INM000011393 CIN: U67120GJ2006PTC047985	 <b>KFin Technologies Limited</b> Address: 301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Mumbai-400070, Maharashtra, India. Tel No.: +91-40 6716 2222 Email: himalaya.ipo@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M Murali Krishna SEBI Registration No.: INR00000221 CIN: L72400MH2017PLC444072	Name: Ms. Pooja Biyani Company Secretary and Compliance officer <b>Himalaya Nutravedics India Limited</b> Address: Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad – 500051, Telangana, India. Telephone: +91 906 349 8493 Email: info@himalayanutravedics.com

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For HIMALAYA NUTRAVEDICS INDIA LIMITED

On behalf of the Board of Directors

Sd/

Date : May 16, 2026

Place : Hyderabad

Pooja Biyani

Company Secretary and Compliance Officer

HIMALAYA NUTRAVEDICS INDIA LIMITED is proposing, subject to, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DRHP on May 15, 2026. The DRHP [along with Draft Abridge Prospectus] shall be available on the website of the SME platform of BSE i.e. <https://www.bsesme.com/> – where equity shares are proposed to be listed, on the website of the Company i.e. <https://www.himalayanutravedics.com>; and the website of the BRLM, i.e. Nirbhaya Capital Services Private Limited at [www.nirbhayacapital.com](http://www.nirbhayacapital.com). Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 26 of the DRHP. Potential investors should not rely on the DRHP for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in "offshore transactions" as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

POST-OFFER ADVERTISEMENT IN ACCORDANCE WITH REGULATION 18(12) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AS AMENDED, FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF

**N2N TECHNOLOGIES LIMITED**

("Target Company")

CIN: L72900PN1985PLC145004

Registered Office: 909, Budhwar Peth, Opp Gujrat Lodge, Pune 411002 Maharashtra, India

Tel. No: +91 91674 17504 • Email id: investors@n2ntechno.com • Website: <https://n2ntechno.com/>

Open Offer for acquisition of up to 12,91,228 equity shares of face value of ₹ 10/- each at a price of ₹ 4.30/- per fully paid up equity share representing 40% of the Expanded Voting Capital to the public shareholders of N2N Technologies Limited ("Target Company") by Harmony Remedies India Private Limited ("Acquirer"), along with Mr. Firoze Nariman Kapadia (PAC 1) and Ms. Aditi Vipin Parikh (PAC 2) Representing Directors of Acquirer, hereinafter collectively referred as Person acting in concert or PACs for the purpose of the Open Offer, pursuant to regulations 4 and other applicable provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations").

This Post Offer Advertisement is being issued by Inga Ventures Private Limited, the Manager to the Offer ("Manager"), on behalf of the Acquirer along with PACs, in compliance with Regulation 18 (12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations") in respect of Open Offer ("Post Offer Advertisement")

This Post Offer Advertisement should be read in continuation of, and in conjunction with the:

- Public announcement dated October 27, 2025 ("PA" or "Public Announcement");
- Detailed Public Statement ("DPS") dated November 03, 2025;
- Letter of Offer dated April 20, 2026, along with the Form of Acceptance-cum-Acknowledgement ("Letter of Offer" or "LOF"); and
- Pre-offer advertisement cum corrigendum to the DPS dated April 28, 2026 ("Pre-Offer Advertisement cum Corrigendum"), which was published on April 29, 2026 in all the newspapers in which the DPS was published.

This Post Offer Advertisement is being published in all the newspapers in which the DPS was published.

Capitalised terms used but not defined in this Post Offer Advertisement shall have the same meaning assigned to such terms in the LOF and the Pre-Offer Advertisement cum Corrigendum.

1	Name of the Target Company	N2N Technologies Limited			
2	Name of the Acquirer	Harmony Remedies India Private Limited			
3	Name of Person Acting in Concerts (PACs)	PAC 1 : Mr. Firoze Nariman Kapadia PAC 2 : Ms. Aditi Vipin Parikh			
4	Name of the Manager to the Offer	Inga Ventures Private Limited			
5	Name of the Registrar to the Offer	MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)			
6	Offer Details				
(a)	Date of Opening of the Offer	Thursday April 30, 2026			
(b)	Date of Closure of the Offer	Thursday May 14, 2026			
7	Date of Completion of Payment of Consideration and communication of Rejection/Acceptance	Not applicable as no equity share have been tendered in this Open Offer			
8	Details of Acquisition	Proposed in the Offer Document		Actual	
8.1	Offer Price	Rs. 4.30/-		Rs. 4.30/-	
8.2	Aggregate number of shares tendered	Nil		Nil	
8.3	Aggregate number of shares accepted	Nil		Nil	
8.4	Size of the Offer (Number of shares multiplied by offer price per share)	Rs.55,52,28,04 /-		Rs. 55,52,28,04 /-	
		Number	In %	Number	In %
8.5	Shareholding of the Acquirer before Agreements / Public Announcement	Nil		Nil	
8.6	Shares Acquired by way of Agreements	Nil		Nil	
8.7	Shares Acquired by way of Preferential Issue	Nil		Nil	
8.8	Shares Acquired by way of Open Offer	Nil		Nil	
8.9	Shares acquired after Detailed Public Statement	Nil		Nil	
8.10	Post Offer Shareholding of Acquirer along with PACs	Nil		Nil	
8.11	Pre & Post offer shareholding of the Public*	Pre Offer	Post Offer	Pre Offer	Post Offer
	Number	16,02,089		16,02,089	
	In %	49.63		49.63	

\*Details of the same have been taken from the website of BSE Limited as Nil share has been tendered.

Capitalized terms used in this announcement, but not defined, shall have the same meaning assigned to them in the PA, DPS and the Letter of Offer. All other terms and conditions of the Offer shall remain unchanged.

The Acquirer along with PACs accept the responsibility for the information contained in this Announcement and also for the obligations of the Acquirer along with PACs laid down in the SEBI (SAST) Regulations and subsequent amendments made thereof.

A copy of this Post Offer Advertisement will also be available on the SEBI website at [www.sebi.gov.in](http://www.sebi.gov.in), BSE website at [www.bseindia.com](http://www.bseindia.com) and will be dispatched to the Registered Office of the Target Company.

Issued by the Manager to the Offer on behalf of the Acquirer and PACs:

MANAGER TO THE OFFER	REGISTRAR TO THE OFFER
 <b>INGA</b> Inga Ventures Private Limited 1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India Tel. No.: +91 22 68540808 Email: projectn2n@ingaventures.com Contact Person: Kavita Shah SEBI Registration Number: INM000012698	 <b>MUFG</b> MUFG Intime MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) C-101, 1st Floor, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400083, Maharashtra, India Tel. No.: +91 810 811 4949 Email: n2ntechnologies.offer@in.mpmms.mufg.com Contact Person: Pradnya Karanjekar SEBI Registration Number: INR000004058

For and on behalf of the Acquirer and PACs

Sd/-

Harmony Remedies India Private Limited

Place : Mumbai

Date : May 18, 2026